- Home
- CRGY vs LGND Comparison
CRGY vs LGND Comparison
Compare CRGY & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRGY | LGND |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRGY | LGND |
|---|---|---|
| Price | $12.02 | $205.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $13.25 | ★ $245.17 |
| AVG Volume (30 Days) | ★ 7.9M | 151.1K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $3,579,782,000.00 | N/A |
| Revenue This Year | $26.77 | $0.74 |
| Revenue Next Year | N/A | $19.04 |
| P/E Ratio | $99.08 | ★ $76.27 |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $6.83 | $93.58 |
| 52 Week High | $12.40 | $212.49 |
Technical Indicators
Market Signals| Indicator | CRGY | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 60.47 |
| Support Level | $8.29 | $179.55 |
| Resistance Level | $12.40 | $207.72 |
| Average True Range (ATR) | 0.55 | 8.22 |
| MACD | 0.07 | 1.89 |
| Stochastic Oscillator | 85.63 | 85.91 |
Price Performance
Historical ComparisonAbout CRGY Crescent Energy Company
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.